↓ Skip to main content

Eptinezumab for the prevention of chronic migraine: efficacy and safety through 24 weeks of treatment in the phase 3 PROMISE-2 (Prevention of migraine via intravenous ALD403 safety and efficacy–2…

Overview of attention for article published in The Journal of Headache and Pain, October 2020
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (95th percentile)
  • High Attention Score compared to outputs of the same age and source (86th percentile)

Mentioned by

news
7 news outlets
twitter
1 X user
patent
1 patent

Citations

dimensions_citation
62 Dimensions

Readers on

mendeley
91 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Eptinezumab for the prevention of chronic migraine: efficacy and safety through 24 weeks of treatment in the phase 3 PROMISE-2 (Prevention of migraine via intravenous ALD403 safety and efficacy–2) study
Published in
The Journal of Headache and Pain, October 2020
DOI 10.1186/s10194-020-01186-3
Pubmed ID
Authors

Stephen Silberstein, Merle Diamond, Nada A. Hindiyeh, David M. Biondi, Roger Cady, Joe Hirman, Brent Allan, Susan Pederson, Barbara Schaeffler, Jeff Smith

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 91 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 91 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 15 16%
Student > Bachelor 13 14%
Other 12 13%
Student > Master 6 7%
Student > Postgraduate 4 4%
Other 7 8%
Unknown 34 37%
Readers by discipline Count As %
Medicine and Dentistry 20 22%
Neuroscience 16 18%
Pharmacology, Toxicology and Pharmaceutical Science 10 11%
Biochemistry, Genetics and Molecular Biology 5 5%
Nursing and Health Professions 3 3%
Other 2 2%
Unknown 35 38%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 56. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 23 March 2023.
All research outputs
#686,776
of 23,849,058 outputs
Outputs from The Journal of Headache and Pain
#70
of 1,417 outputs
Outputs of similar age
#20,513
of 416,697 outputs
Outputs of similar age from The Journal of Headache and Pain
#4
of 30 outputs
Altmetric has tracked 23,849,058 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 97th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,417 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 17.6. This one has done particularly well, scoring higher than 95% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 416,697 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 95% of its contemporaries.
We're also able to compare this research output to 30 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 86% of its contemporaries.